ELPIS II Misses Its Phase IIb Ventricular Endpoint

Company Longeveron Event Type Clinical Trial Readout Modality Cell Therapy (Allogeneic Mesenchymal Stromal Cells) Asset Laromestrocel Target Paracrine Pro-Vascular / Anti-Inflammatory Signaling (Non-Specific) Disease Area Hypoplastic Left Heart Syndrome Summary Laromestrocel did not improve the primary Month-12 right-ventricular ejection-fraction endpoint in the randomized, 40-infant ELPIS…